ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RMD / forecast
DXCM (76) MDLN (44) WST (81) BDX (67) ⌘ Pro Terminal →

ResMed Inc. (RMD) 12-Month Stock Forecast & Price Target Cone

$229.94 -9.05% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $226.75

ResMed Inc. (RMD) earns a Roarable Rating of A (Strong Buy) with 86/100 RQD Confidence. High-quality cash engine (59% profit margin, 23% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate) →
ROARABLE A • STRONG BUY Cap $35.56B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, ResMed Inc. (NYSE: RMD) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $229.94 (-9.05% 1D, market cap $35.56B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RMD ranks #3 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RMD compare to DXCM and MDLN in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A (86/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RMD?
▼

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $226.74 (-1.39%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 32.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 86/100 (A) historically ranked in the Top 5% of excess returns over the next 90 days (+9.2% avg 90D alpha vs SPY • 73.2% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSTRONG BUY • A
025507510086
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A · Rk A-
Cash (19)Whales (17)SEC (18)Macro (15)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+12.6% Base Target
$306 Bull$259 Base$189 Bear
📬 FREE RMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMD)Realized 20D OHLCV Swing Band: ±5.2%
Deterministic 5-Pillar Attribution (86/100 Composite)
🔍 WHY RMD SCORES 86/100 (A) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 32.3% FCF Margin ($1.66B FCF) & 59.4% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (21% of score)

Altman Z-Score 12.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit15/20 pts (-5 pt drag)

Macro rate sensitivity & RSI-14 (60.1) create a -5 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
94
Grade A+$235.04+4.5% Next Q
Q2 (-2Q)
91
Grade A+$245.50+2.2% Next Q
Q3 (-1Q)
89
Grade A$250.80-8.3% Next Q
Current
86
Grade A$229.94+9.2% Hist 90D α
Trajectory: A+ (94) → A (86)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 86/100 (A) score, RMD faces multiple-compression risk if 25.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 56.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($232.63) or 200D SMA ($224.82) invalidates the momentum regime and cuts Target Base ($258.91) toward Bear Floor ($188.55).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RMD Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 86%NO 14%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RMD Position Size: $10,000

Shares at $229.94: 43.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $188.55
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $258.91
$11,260
+$1,260 (+12.6%)
12M Bull Case BreakoutTarget $305.51
$13,287
+$3,287 (+32.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 32● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$26974%A
Goldman SachsSector Coverage LeadSTRONG BUY$28769%B
JP MorganUS Large-Cap ResearchHOLD$22458%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.79%🛡️ HOLDING TREND SUPPORT
2026-11-02O $250.2H $252.8L $229.9C $229.9VOL 1.45M
RES: $258.1SUP: $229.4SMA50: $232.6SMA200: $224.8
$260.8$239.0$217.2$195.3$173.5RES $258.1SUP $229.4$229.92026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RMD Butterfly Map → + Track RMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
19.1%/yr Implied 5Y Growth

vs. +9.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
LLY → RMD Analyst Hypothesis
FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity introduces the first pharmacologic disease-modifying competitor to ResMed CPAP devices.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMD)

Health Care Rank #3 of 1016 ⚔️ DXCM vs RMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMD vs. DXCM, MDLN, WST, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ResMed Inc. (RMD) ranks #3 by composite RQD confidence (86/100, grade A) and #50 by equity capitalization ($35.56B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently leads its immediate peer cohort in composite quantitative strength at 86/100 (A).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RMD ACTIVE
ResMed Inc.
A 86/100 25.4x 59.4% 22.9% -9.05% $35.56B Benchmark Subject
DXCM
DexCom Inc.
B+ 76/100 36.1x 60.1% 21.6% +2.95% $30.16B /dxcm-vs-rmd →
MDLN
Medline Inc.
D 44/100 — — 8.2% +0.38% $42.07B /mdln-vs-rmd →
WST
West Pharmaceutical Services Inc.
A- 81/100 59.4x 35.9% 17.9% -0.97% $29.32B /wst-vs-rmd →
BDX
Becton Dickinson and Company
C+ 67/100 32.2x 45.4% 4.9% -0.23% $54.03B /bdx-vs-rmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000943819

In its most recent audited fiscal period (FY2025, filed 2025-06-30), ResMed Inc. (RMD) reported GAAP revenue of $5.15B (+9.8% vs. FY2024 revenue of $4.69B , and +21.9% cumulative change since FY2023) , GAAP net income of $1.40B, operating cash flow of $1.75B, and free cash flow of $1.66B (+27.6% YoY). On the balance sheet, RMD closed FY2025 with $8.50B in total assets against $982.1M in total debt (Altman Z-Score: 12.49, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $5.15B $1.40B $1.75B $1.66B $8.50B $982.1M
FY2024 (FY) 2024-06-30 $4.69B $1.02B $1.40B $1.30B $7.14B $849.7M
FY2023 (FY) 2023-06-30 $4.22B $898.0M $693.3M $503.3M $19.56B $4.58B

3. RMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, ResMed Inc. (NYSE: RMD) is rated A (Strong Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 86/100 at a spot price of $229.94 (-9.05% 1D, market cap $35.56B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, RMD ranks #3 in composite RQD confidence.

How does RMD compare to DXCM and MDLN in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), RMD carries a Roarable A (86/100 RQD), trailing P/E of 25.4x, gross margin of 59.4%, and ROIC of 22.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (76/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.16B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RMD?

Per RMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000943819), ResMed Inc. generated $5.15B in revenue (+9.8% YoY), $1.40B in net income, and $1.66B in free cash flow against $8.50B in total assets and $982.1M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RMD last traded at $229.94 (-9.05% on volume of 3,470,546 shares), positioning the stock -1.16% below its 50-day simple moving average ($232.63) and +2.28% above its 200-day simple moving average ($224.82). Across its 52-week range of $180.27 to $277.67, RMD sits at the 51.0% percentile with a 14-day RSI of 60.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($217.98 to $241.90).

RMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RMD's 12-month stock price target?

ResMed Inc. (RMD) carries a 12-month consensus base price target of $258.91 (+12.6% from $229.94), with a bull-case target of $305.51 and a bear-case floor of $188.55.

Is RMD stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates RMD A (Strong Buy — BUY) with an RQD Confidence score of 86/100.

Direct Sub-Reports: RMD RQD Cockpit RMD 12M Forecast RMD Earnings & Move RMD Dividends & DRIP RMD Insiders & 13F RMD Whale Options RMD Profit Sankey RMD News & Why
ROARABLE RATING BRIEF • RQD 86/100 (A) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RMD — ResMed Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 86, graded A, with the verdict "Roarable Strong Buy — Excellent Cash & Whale Support." Per the Roarable RQD rating, the five pillars score as follows: Fundamental Cash Engine 19/20 (ROIC 22.9%; FCF yield 4.67%), Whale 13F Flow 17/20 (institutional accumulation and options positioning), Insider Conviction 17/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 15/20 (beta 0.93; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 12.49; Piotroski F 9/9; Debt/Equity 0.15). For a prospective investor, the strongest support comes from cash generation and balance-sheet quality, which the rating treats as the highest-weighted evidence. The lowest-scoring pillar is macro regime fit, which indicates the stock's sensitivity to sector and market conditions is less favorable than its internal fundamentals. Valuation is a tradeoff: per the Snapshot data, the stock trades at 25.4x trailing earnings and 23.6x forward earnings, so the rating's cash-quality support must be weighed against a multiple that is not low. The rating is a structured summary of the source data and does not constitute personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$252.83$35.56B25.423.619.99.960.87%0.93$180.27 - $277.6722.9%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$5146.3M$1685.4M$1401.0MN/A$1661.7M$1417.1M$982.1M
FY 2024$4685.3M$1319.9M$1021.0MN/A$1301.8M$521.9M$849.7M
FY 2023$4223.0M$1131.9M$898.0MN/A$503.3MN/A$4576.3M

Per the market data, gross margin is 59.4%, operating margin 32.7%, and net margin 27.2%, with ROIC of 22.9%. Per the Roarable RQD rating, the Altman Z-Score is 12.49 and the Piotroski F-Score is 9/9, with Debt/Equity of 0.15. Revenue and net income rose across the three reported periods, and FY 2025 free cash flow was $1661.7M. The FY 2023 debt figure ($4576.3M) is markedly higher than the FY 2024 and FY 2025 figures and is not explained in the source data.

Open Questions

  • What is the company's revenue split by product line and customer segment, and how much is device versus mask re-supply?
  • What is the undisclosed exposure estimate cited in the 10-K for GLP-1 substitution, and what is the observed OSA script trend?
  • Why does FY 2023 debt ($4576.3M) differ so sharply from FY 2024 and FY 2025, and what does the reported cash balance look like for FY 2023?
  • What drove the recent share-price move reported in the news feed, given that article bodies are not provided?
  • What are the analyst consensus, price targets, and recent insider or 13F transactions that underpin the whale and insider pillar scores?

RMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ResMed Inc. (RMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RMD Bull vs. Bear Conversation Board — What's Your Call at $229.94?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $298.34 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RMD (A • RQD 86/100) a Buy at $252.83?

Welcome to the RMD (ResMed Inc.) Roar Pit. Current RQD Composite is 86/100 (Roarable Strong Buy — Excellent Cash & Whale Support) in Medical/Dental Instruments. Bulls point to capital efficiency (22.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $212.38 (-16.0%)
Spot @ $252.83

Pump the brakes on RMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RMD, but look at what you are paying: 25.4x trailing P/E with 59.4% gross margins. Unless ResMed Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $288.23 (+14.0%)
Spot @ $252.83

RMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $252.83 (52-wk range $180.27 - $277.67), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%